Colosimo, F.A.; Borsellino, P.; Krider, R.I.; Marquez, R.E.; Vida, T.A.
The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness. Psychoactives 2024, 3, 93-122.
https://doi.org/10.3390/psychoactives3010007
AMA Style
Colosimo FA, Borsellino P, Krider RI, Marquez RE, Vida TA.
The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness. Psychoactives. 2024; 3(1):93-122.
https://doi.org/10.3390/psychoactives3010007
Chicago/Turabian Style
Colosimo, Frankie A., Philip Borsellino, Reese I. Krider, Raul E. Marquez, and Thomas A. Vida.
2024. "The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness" Psychoactives 3, no. 1: 93-122.
https://doi.org/10.3390/psychoactives3010007
APA Style
Colosimo, F. A., Borsellino, P., Krider, R. I., Marquez, R. E., & Vida, T. A.
(2024). The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness. Psychoactives, 3(1), 93-122.
https://doi.org/10.3390/psychoactives3010007